Slide 1: First Quarter 2026 Earnings Call
First Quarter 2026 Earnings Call MAY 5, 2026 ©2026 Myriad Genetics, Inc.
Slide 2: Forward-looking statements and Non-GAAP financial measures
Forward-looking statements and Non-GAAP financial measures Some of the FORWARD-LOOKING STATEMENTS AND DISCLAIMERS information presented These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these here today contains
Slide 3: Progress
Progress Sam Raha PRESIDENT AND CHIEF EXECUTIVE OFFICER ©2026 Myriad Genetics, Inc. 3
Slide 4: First quarter 2026 performance and takeaways
First quarter 2026 performance and takeaways Advancing Cancer Care Continuum + preparing for multiple new test launches Strong Cancer Care Continuum Investing ahead of a robust Advancing Cancer Care test volume growth new product cycle Continuum strategy Q1‘26 revenue of $200.4M, or 2% 68.7% gross m
Slide 5: Entering MRD market with a differentiated approach
Entering MRD market with a differentiated approach MARKET DRIVERS HIGHLIGHTS Growing market awareness • Complements Myriad Genetics’ of the importance of ultra- portfolio of tests across the sensitive detection Cancer Care Continuum Community oncologist • Deploying dedicated MRD preference for sales
Slide 6: Business Update
Business Update Brian Donnelly CHIEF COMMERCIAL OFFICER ©2026 Myriad Genetics, Inc. 6
Slide 7: Continue to drive strong Hereditary Cancer test growth; Launched Precise MRD
CANCER CARE CONTINUUM Continue to drive strong Hereditary Cancer test growth; Launched Precise MRD Operational results: First quarter 2026 $120.2M Q1‘26 revenue and recent highlights • Hereditary cancer testing continued double digit volume growth trend in Q1‘26 ~96K Q1‘26 volume • Solid Prolaris vo
Slide 8: On track for H2'26 launch of FirstGene multiple prenatal screen
P R E N ATA L H E A LT H On track for H2‘26 launch of FirstGene multiple prenatal screen Operational results: First quarter 2026 $41.9M Q1‘26 revenue and recent highlights • CIGNA updated its medical policy to cover expanded carrier screen panels, including ~153K Foresight Universal Plus, starting A
Slide 9: Maintaining leadership with disciplined level of investment and focus
M E N TA L H E A LT H Maintaining leadership with disciplined level of investment and focus Operational results: First quarter 2026 $38.3M Q1‘26 revenue and recent highlights • • 39K clinicians ordered GeneSight in Q1‘26 Improvement in GeneSight average revenue per ~136K Q1‘26 volume test reflects i
Slide 10: Taking actions designed to deliver strategic growth
Taking actions designed to deliver strategic growth Investing in the Cancer Care Continuum Focus on driving commercial success Improving share of voice Expanding demand Preparing for critical with target customers generation capabilities product launches Meaningfully increased Continuing to build an
Slide 11: Financial Update
Financial Update Ben Wheeler CHIEF FINANCIAL OFFICER ©2026 Myriad Genetics, Inc. 11
Slide 12: First quarter key volume growth drivers
First quarter key volume growth drivers Select test volume and growth rates All figures in thousands, except growth rates Cancer Care Continuum* Mental Health Additional highlights: Within Cancer Care Continuum: o Hereditary Cancer testing 150 150 7% volume grew 14% YOY in Q1‘26 13% o Prolaris and P
Slide 13: First quarter 2026 financial performance
First quarter 2026 financial performance Investing ahead of new product cycle All figures in millions, except per share amounts and percentages Total revenue Gross Margin Adjusted Operating Expense* Adjusted EPS* Increased Increased Increased Lower by 2% 20bps 6% $0.06 YOY Q1‘26 70% YOY Q1‘26 YOY Q1
Slide 14: Strong gross profit and healthy liquidity position
Strong gross profit and healthy liquidity position Additional highlights: Q1‘26 adj operating cash Gross Profit Adjusted EBITDA1 Liquidity position2 flow1 was $(13M) Generated approximately Generated a loss of Access to Q1‘26 adj free cash flow1 $138M $5M ~$199M was $(20M) As of March 31, 2026 in Q1
Slide 15: Reaffirming 2026 financial guidance
Reaffirming 2026 financial guidance All figures in millions, except percentages 2026 FINANCIAL COMMENTS GUIDANCE Reiterate the full year 2026 revenue range, reflecting current business Total trends. Revenue $860 - 880 Expect 2H’26 revenue to be greater than 1H’26 Adjusted Gross margins expected to f
Slide 16: Catalysts to watch in 2026E
Catalysts to watch in 2026E HCT Prostate Cancer Precise MRD Prenatal Health • Launch of MyRisk • Launch Prolaris AI Initiate commercial testing for • Report out on FirstGene Disease Specific test; Q2‘26 select customers; March‘26 CONNECTOR study; Panels; H1‘26 H1‘26 • Prolaris meta-analysis • MolDx
Slide 17: Q&A
Q&A ©2026 Myriad Genetics, Inc. 17
Slide 18: Appendix
Appendix ©2026 Myriad Genetics, Inc. 18
Slide 19: Reconciliation of GAAP to Non-GAAP – Adjusted Gross Margin
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months Ended March 31, 2026 and 2025 – Adjusted Gross Margin (unaudited data in millions) Three months ended March 31, 2026 2025 Adjusted Gross Margin Gross Profit $ 137.6 $ 134.2 Acquisition - amortization of intangible assets(1) 0
Slide 20: Reconciliation of GAAP to Non-GAAP – Adjusted Operating Expenses
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months Ended March 31, 2026 and 2025 – Adjusted Operating Expenses (unaudited data in millions) Three months ended March 31, 2026 2025 Adjusted Operating Expenses Operating Expenses $ 168.3 $ 163.2 Acquisition - amortization of inta
Slide 21: Reconciliation of GAAP to Non-GAAP – Adjusted Operating Expenses (Cont.)
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months Ended March 31, 2026 and 2025 – Adjusted Operating Expenses (Cont.) (1) Represents recurring amortization charges resulting from the acquisition of intangible assets. (2) Expense related to goodwill and long-lived asset impai
Slide 22: Reconciliation of GAAP to Non-GAAP – Adjusted Net Loss
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months Ended March 31, 2026 and 2025 – Adjusted Net Loss (unaudited data in millions, except per share amounts) Three months ended March 31, 2026 2025 Adjusted Net Loss(1) Net Loss $ (34.1) $ (0.1) Acquisition - amortization of inta
Slide 23: Reconciliation of GAAP to Non-GAAP – Adjusted Net Loss (Cont.)
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months Ended March 31, 2026 and 2025 – Adjusted Net Loss (Cont.) (1) To determine Adjusted Loss Per Share. (2) Represents recurring amortization charges resulting from the acquisition of intangible assets. (3) Expense related to goo
Slide 24: Reconciliation of GAAP to Non-GAAP – Adjusted EBITDA
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months Ended March 31, 2026 and 2025 – Adjusted EBITDA (unaudited data in millions) Three months ended March 31, 2026 2025 Adjusted EBITDA Net Loss $ (34.1) $ (0.1) Acquisition - amortization of intangible assets(1) 6.5 9.1 Deprecia
Slide 25: Reconciliation of GAAP to Non-GAAP – Adjusted EBITDA (Cont.)
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months Ended March 31, 2026 and 2025 – Adjusted EBITDA (Cont.) (1) Represents recurring amortization charges resulting from the acquisition of intangible assets. (2) Consists of depreciation expense recognized during the period. (3)
Slide 26: Reconciliation of GAAP to Non-GAAP – Adjusted Free Cash Flow
Reconciliation of GAAP to Non-GAAP Financial Measures for the Three Months Ended March 31, 2026 and 2025 – Adjusted Free Cash Flow (unaudited data in millions) Three months ended March 31, 2026 2025 Adjusted Operating and Free Cash Flow Net Cash Used in Operating Activities $ (15.7) $ (16.3) Real es